Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.
When sloan ratio (-34.95)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.
As of Jun. 2025, Relief Therapeutics Holding has a Sloan Ratio of -40.07%, indicating earnings are more likely to be made up of accruals.
Relief Therapeutics Holding (XSWX:RLF) Sloan Ratio % Explanation
A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.
If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.
If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.
If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.
As of Jun. 2025, Relief Therapeutics Holding has a Sloan Ratio of -40.07%, indicating earnings are more likely to be made up of accruals.
Relief Therapeutics Holding Sloan Ratio % Related Terms
Relief Therapeutics Holding Sloan Ratio % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:RLF vs KTTA, OSRH, LIMN: Sloan Ratio % Comparison
For the Biotechnology subindustry, Relief Therapeutics Holding's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relief Therapeutics Holding Sloan Ratio % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's Sloan Ratio % distribution charts can be found below:
* The bar in red indicates where Relief Therapeutics Holding's Sloan Ratio % falls into.
Relief Therapeutics Holding Sloan Ratio % Calculation
Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.
For company reported semi-annually, GuruFocus uses latest two semi-annual data as the TTM data.
Relief Therapeutics Holding's Net Income for the trailing twelve months (TTM) ended in Jun. 2025 was -12.562 (Dec. 2024 ) + -4.478 (Jun. 2025 ) = CHF-17.04 Mil.
Relief Therapeutics Holding's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 was 0.25 (Dec. 2024 ) + -3.76 (Jun. 2025 ) = CHF-3.51 Mil.
Relief Therapeutics Holding's Cash Flow from Investing for the trailing twelve months (TTM) ended in Jun. 2025 was 4.408 (Dec. 2024 ) + 1.288 (Jun. 2025 ) = CHF5.70 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Relief Therapeutics Holding (XSWX:RLF) has a Sloan Ratio % of -40.07% as of Jun. 2025. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Relief Therapeutics Holding and its competitors.
Is Relief Therapeutics Holding's Sloan Ratio % too high?
Relief Therapeutics Holding's current Sloan Ratio % is -40.07%. Overall, Relief Therapeutics Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Relief Therapeutics Holding's Sloan Ratio % compare to KTTA and OSRH?
Relief Therapeutics Holding's Sloan Ratio % of -40.07% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Sloan Ratio % for a Biotechnology company?
A good Sloan Ratio % depends on the Biotechnology industry context. However, Sloan Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Sloan Ratio % mean?
A high Sloan Ratio % can signal that a stock is expensive relative to its fundamentals. Sloan ratio measures earnings quality based on the amount of accruals. View historical data on Relief Therapeutics Holding and its competitors. Relief Therapeutics Holding's current Sloan Ratio % is -40.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relief Therapeutics Holding stock overvalued right now?
Relief Therapeutics Holding (XSWX:RLF) has a current Sloan Ratio % of -40.07%. The stock's GF Value™ is CHF6.28, compared to a current price of CHF3.00 — trading 52.2% below its estimated fair value. The current Sloan Ratio % is -40.07%. Relief Therapeutics Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Sloan Ratio % calculated?
Sloan Ratio % is calculated from a company's financial statements. For Relief Therapeutics Holding (XSWX:RLF), the current Sloan Ratio % is -40.07% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Relief Therapeutics Holding (XSWX:RLF) Overvalued in 2026?
Based on GuruFocus' analysis, Relief Therapeutics Holding stock appears to be undervalued.
The current stock price of CHF3.00 is trading 52.2% below its estimated GF Value™ of CHF6.28.
Key valuation signals for XSWX:RLF:
Sloan Ratio %: -40.07%
GF Value™: CHF6.28 vs. price of CHF3.00 (52.2% below fair value)
No single metric tells the full story. See the XSWX:RLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products, and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Its pipeline includes various drug candidates in their different stages of development, such as RLF-TD011 and RLF-100, among others. It also has commercial legacy products like Cambia, Setofilm, Voltadol, and Voltfast, among others. Geographically, the company generates a majority of its revenue from Europe (excluding Switzerland) and the rest from North America, Switzerland, and the rest of the world.
20GF Score
Get the complete analysis for XSWX:RLF
Sloan Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:RLF has been successfully added to your 
